<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619407</url>
  </required_header>
  <id_info>
    <org_study_id>BB 179/20</org_study_id>
    <nct_id>NCT04619407</nct_id>
  </id_info>
  <brief_title>Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers</brief_title>
  <acronym>COKITS</acronym>
  <official_title>Screening for SARS-CoV-2-Infections in Teachers, Childcare Educators, Pupils and Preschoolers in the State of Mecklenburg-Vorpommern</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Science and Culture of the State of Mecklenburg-Vorpommern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Social Affairs, Integration and Equality of the State of Mecklenburg-Vorpommern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Office for Health and Social Affairs of the State of Mecklenburg-Vorpommern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are&#xD;
&#xD;
        1. to establish the prevalence of SARS-CoV-2 in schools and kindergartens in the State of&#xD;
           Mecklenburg-Vorpommern in autumn and winter 2020/2021&#xD;
&#xD;
        2. to monitor the future spread of the disease by assessing serological responses to&#xD;
           SARS-CoV-2 in teachers and childcare educators over time&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      This study aims to collect information on teachers and childcare educators as well as on&#xD;
      pupils and preschoolers in the State of Mecklenburg-Vorpommern&#xD;
&#xD;
      Over a 5 month period, 5 study visits per participant are planned. At each visit,&#xD;
      nasal/throat swabs (for PCR testing) will be collected and participants will be asked to fill&#xD;
      in a questionnaire (asking for SARS-CoV-2 risk factors, perceived risk, and impact of the&#xD;
      pandemic on their quality of life). In adults, additional blood samples (for SARS-CoV-2&#xD;
      antibody testing) will be collected at the first and the last study visit. This will help to&#xD;
      gain a better understanding of viral load and antibody development over time.&#xD;
&#xD;
      The remaining blood samples will be stored in a repository for future research.&#xD;
&#xD;
      The study is part of a modular SARS-CoV-2-research programme of the University Medicine&#xD;
      Greifswald.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>5 months</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of SARS-CoV-2 antibodies</measure>
    <time_frame>At study inclusion</time_frame>
    <description>Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of SARS-CoV-2 antibodies</measure>
    <time_frame>5 months</time_frame>
    <description>Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>At study inclusion</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>2 months</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life</measure>
    <time_frame>5 months</time_frame>
    <description>As assessed by a monthly questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>At study inclusion</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of participants with SARS-CoV-2 detectable in PCR</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>teacher</arm_group_label>
    <description>Employed in a school in Mecklenburg-Vorpommern&#xD;
Age between 18 to 67 years&#xD;
Willing and able to provide informed consent&#xD;
Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pupils</arm_group_label>
    <description>Attending school in Mecklenburg-Vorpommern&#xD;
Age between 6 to 17 years&#xD;
Agreement to participate&#xD;
Legal representative willing and able to provide informed consent&#xD;
Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>childcare educators</arm_group_label>
    <description>Employed in a kindergarten in Mecklenburg-Vorpommern&#xD;
Age between 18 to 67 years&#xD;
Willing and able to provide informed consent&#xD;
Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preschoolers</arm_group_label>
    <description>Attending kindergarten in Mecklenburg-Vorpommern&#xD;
Age between 3 to 6 years&#xD;
Agreement to participate&#xD;
Legal representative willing and able to provide informed consent&#xD;
Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasopharyngeal swab</intervention_name>
    <description>SARS-CoV-2 PCR</description>
    <arm_group_label>childcare educators</arm_group_label>
    <arm_group_label>preschoolers</arm_group_label>
    <arm_group_label>pupils</arm_group_label>
    <arm_group_label>teacher</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum testing</intervention_name>
    <description>Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)</description>
    <arm_group_label>childcare educators</arm_group_label>
    <arm_group_label>teacher</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, nasal/throat swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Teachers and childcare educators as well as pupils and preschoolers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  See cohort descriptions&#xD;
&#xD;
          -  Willing to have blood samples stored for future research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils-Olaf Hübner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karsten Becker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nils-Olaf Hübner, Prof. Dr.</last_name>
    <phone>+49383486</phone>
    <phone_ext>4833</phone_ext>
    <email>nils.huebner@med.uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lena Ulm, Dr.</last_name>
    <phone>+49383486</phone>
    <phone_ext>5584</phone_ext>
    <email>lena.ulm@med.uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greifswald University Medicine</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils-Olaf Hübner, Prof. Dr.</last_name>
      <phone>+49383486</phone>
      <phone_ext>4483</phone_ext>
      <email>nils.huebner@med.uni-greifswald.de</email>
    </contact>
    <contact_backup>
      <last_name>Lena Ulm, Dr.</last_name>
      <phone>+49383486</phone>
      <phone_ext>5584</phone_ext>
      <email>lena.ulm@med.uni-greifswald.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serology</keyword>
  <keyword>antibody formation</keyword>
  <keyword>epidemiology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

